Skip to main content
Signal8

Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder

$PTIXPress releaseNov 11, 2026, 8:30 AM ETRead the release

Protagenic Therapeutics announced a private placement providing $1.5 million in upfront gross proceeds, with up to $3.5 million more available if two series of milestone-linked warrants are exercised in full, for total potential gross proceeds of up to $5 million. Proceeds will fund IND-enabling activities for PT00114 and initiate a planned Phase 1/2a trial in Generalized Anxiety Disorder, with first patient dosing targeted for Q2 2027. FDA pre-IND feedback identified no deficiencies that would preclude an IND submission.

Key figures

Deal Value Usd
5000000
Shares Offered
0
Topline safety data
H2 2027
Upfront gross proceeds
$1.5 million
Exploratory efficacy data
H1 2028
First patient dosing target
Q2 2027
Total potential gross proceeds
$5 million
Milestone warrant potential proceeds
$3.5 million

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.